Brief: Alebund Pharmaceuticals (Jiangsu) Says IND Application For AP308 Cleared By U.S. FDA
08/09/2026 16:21
BRIEF-Alebund Pharmaceuticals (Jiangsu) Says IND Application For AP308 Cleared By U.S. FDA Sept 8 (Reuters) - Alebund Pharmaceuticals (Jiangsu) Ltd 9637.HK:
INVESTIGATIONAL NEW DRUG APPLICATION FOR AP308 FOR TREATMENT OF IGA NEPHROPATHY CLEARED BY U.S. FDA
Further company coverage: 9637.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Alebund Pharmaceuticals (Jiangsu)
See all newsBrief: Alebund Pharmaceuticals (Jiangsu) Board Resolves To Repurchase H Shares Up To Hk$100 Million
Brief: Alebund Pharmaceuticals (Jiangsu) Says IND Application For AP308 Cleared By U.S. FDA
Crealights, Baige, Alebund Pharmaceuticals jump in Hong Kong debut
Brief: Alebund Pharmaceuticals (Jiangsu) Sets Final Offer Price At HK$22.6 Per Offer Share